期刊
EUROPEAN UROLOGY
卷 49, 期 1, 页码 92-102出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.eururo.2005.09.016
关键词
lower urinary tract symptoms; benign prostatic hyperplasia; medical consumption; costs; health economic analysis; multi-country study; observational study; TRIUMPH
Objective: To determine the medical consumption and associated treatment costs of patients with LUTS suggestive of BPH. Methods: A prospective, cross-sectional, observational survey in six European countries: France, Germany, Italy, Poland, Spain and the United Kingdom, with a one-year follow-up of incident and prevalent patients. Results: Treatment costs were estimated for 5,057 patients with a mean age of 66 years and a mean IPSS score at inclusion of 11.5. In 30% of patients watchful waiting was the therapy of choice for the full follow-up period, 57% were prescribed alpha-lockers, 11% finasteride and 10% phytotherapy at any moment during the follow-up (including switches and combination of treatment). Surgery rate was 4.9%. Mean one-year treatment costs were 858euro per patient, three quarters of which concerned medication costs. Multivariate regression analysis showed that medication choice, complications and undergoing surgery were associated with higher costs. Conclusions: Treatment costs for patients with LUTS suggestive of BPH were moderate and largely consisted of medication costs. Daily practice and associated costs varied considerably across the six countries. (c) 2005 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据